-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The UK National Institute for Health and Care Excellence (NICE) recommends Tepmetko (tepotinib) for the treatment of adult patients with advanced non-small cell lung cancer ( NSCLC
Lung cancerNSCLC
Tepotinib is the first and only oral MET inhibitor recommended for the treatment of adult patients with advanced NSCLC with a METex14 skipping mutation for the NHS in England, Wales and Northern Ireland
Dr Shobhit Baijal, Consultant Medical Oncologist, University Hospitals NHS Trust, Birmingham, explained: "Existing treatment options for patients with METex14 skipping mutations often show limited progression-free survival and overall survival benefit
NSCLC is a heterogeneous disease with many genomic mutations
In an open-label phase II study, tepotinib (500 mg) was administered to patients with advanced or metastatic NSCLC with METex14 skipping mutations
In the combined biopsy group, the independently reviewed ORR was 46%, and the median duration of response was 11.
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://